Navigation Links
Omixon Founder, Attila Berces Returns as CEO, Aims to Roll-Out New Products
Date:4/22/2020

Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila Berces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017.

In concert between the incoming and outgoing CEOs, as well as Omixon’s Board of Directors, the company has restructured its executive team with Gregory Werner as VP Commercial Operations, Elmar Schilling as CTO, and Judit Kósa as CFO. Gregory Werner joined Omixon from Thermo Fisher where he was responsible for the entire One Lambda portfolio (Transplant Diagnostics) in Europe. Prior to the acquisition by One Lambda, Greg built the European operations for Linkage Biosciences, successfully introducing LinkSeq™ and dominating the market. Elmar Schilling has joined Omixon from Eurofins Genomics, where he led the NGS Manual Innovation Facility at its DNA Campus near Munich. Judit Kósa, joins Omixon after more than a decade in the pharmaceutical industry including Teva Pharmaceuticals and AMRI and more than a decade in CFO roles. "Together with Zoltán Simon (COO), who has been with the company for over 10 years, Omixon's executive team is ready to take Omixon to a new level," says Dr. Berces.

Omixon came to the market with the first HLA genotyping test using Next Generation Sequencing (NGS) in 2014 and has grown revenues at a compounded annual rate of 100% for four consecutive years. “During the fast pace of market expansion we had failed to listen to some customer requirements. We are now addressing this and will provide laboratories with an improved customer experience. We recently released a software update that solved a serious software performance issue. We are committed to continue with our outstanding customer support. We have an ambitious vision to expand our product portfolio by developing new products in-house, as well as by licensing and acquiring new innovative technologies,” says Dr. Berces.

Omixon’s R&D lab continues to operate during the current lock-down. It is an excellent time to gather customer input, improve existing products and develop new ones. The Early Access Program of the 11-locus multiplex Omnitype product is already underway with feedback from 8 labs and while partly interrupted by COVID19, the product versions tested in the second phase of the EAP will incorporate the feedback from those first 8 labs with minimal impact to EAP. We aim to fulfil laboratory expectations and we strive to bring at least one new product on the market every year.

Despite the general economic uncertainty of COVID19, Omixon’s profitability and excellent relationship with its long-term investors allows the company capitalize on growth opportunities with new products in 2020.

Contacts at Omixon
Gregory Werner
VP Commercial Operations
gregory.werner@omixon.com
+41788606847

Nora Nagy, MBA
Market Development Manager
nora.nagy@omixon.com
+36306333050

About Omixon
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 50 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit http://www.omixon.com.

Read the full story at https://www.prweb.com/releases/omixon_founder_attila_berces_returns_as_ceo_aims_to_roll_out_new_products/prweb17058762.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Omixon’s OmniType is Now Available Under Early Access
2. Omixon and TBG form Partnership for Asia Pacific
3. Omixon Announce CE Mark for Holotype HLA
4. Omixon Announces Dimitri Monos as Chair of its Scientific Advisory Board
5. Omixon Announce Major Tender Victory in France
6. Omixon Holotype HLA validation Alpha Study featured at ASHI Annual Meeting 2014
7. Omixon Collaborates with G3 and Genomics England to Validate HLA Genotyping from WGS Data
8. Omixon Launches Holotype HLA for NGS-based HLA Genotyping
9. VetStem Biopharma CEO and Founder, Dr. Bob Harman, Interviewed in New Book "Stem Cell Therapy: A Rising Tide"
10. Animated Dynamics, Inc. Co-Founder, Dr. David Nolte, Receives Award From Purdue University For Commercial Patent
11. Ernst & Young announces Proove Biosciences CEO and Founder, Brian Meshkinas an EY Entrepreneur Of The Year™ 2015 Award Semifinalist in Orange County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2020)... WEST CHESTER, Ohio (PRWEB) , ... April 21, ... ... availability of Biophen™ FXIII chromogenic method for determination of FXIII. , Aniara Diagnostica, ... has strengthened its commitment to meeting today’s highest standards for product quality and ...
(Date:4/7/2020)... LA JOLLA, Calif. (PRWEB) , ... April 06, 2020 , ... ... insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests ... , “ SneakPeek was launched as an ecommerce product, where a mom could ...
(Date:4/1/2020)... ... March 30, 2020 , ... A joint venture between mobile ... earlier this year to bring telehealth to various government agencies, has now focused ... officials are currently?awaiting an Emergency Use Authorization (EUA) waiver from the FDA?to?perform?AI?testing in ...
(Date:4/1/2020)... Conn. (PRWEB) , ... March 31, 2020 , ... ... Science, Inc. (P2) announce the signing of a Joint Development Agreement that ... , Bedoukian Research, Inc. is a global leader in the supply of high-quality ...
Breaking Biology Technology:
(Date:4/28/2020)... SEATTLE, and FT. LAUDERDALE, Fla. (PRWEB) , ... ... ... announces its official launch. The first-of-its-kind category-defining service was started by three teenagers ... to make a change in the world during the time of great need ...
(Date:4/22/2020)... ... , ... RCH Solutions (RCH ), a global provider of Bio-IT computing ... Michael Wlodarczyk as Director of Sales and Business Development. Based out of RCH’s location ... strong presence across the Northeast. , “We continue to see increased demand for specialized ...
(Date:4/18/2020)... MARTINSRIED, Germany and CAMBRIDGE, Mass. (PRWEB) , ... April 16, 2020 ... ... gene delivery technologies for gene and cell therapy, today announced it will present a ... the April 2020 Virtual Investor Summit taking place on April 22 and ...
Breaking Biology News(10 mins):